Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 73Carcinoma, Hepatocellular 67Stomach Neoplasms 52Pancreatic Neoplasms 40Rectal Neoplasms 30Colonic Neoplasms 30Neoplasms 21Liver Neoplasms 20Esophageal Neoplasms 19Neoplasm Metastasis 16Cholangiocarcinoma 16Esophageal Squamous Cell Carcinoma 14Gallbladder Neoplasms 12Biliary Tract Neoplasms 12Lung Neoplasms 10Gastrointestinal Neoplasms 7Adenocarcinoma Of Esophagus 7Ovarian Neoplasms 6Prostatic Neoplasms 5Neoplasms by Site 5Bile Duct Neoplasms 5Adenocarcinoma 5Polyps 4Neoplasms by Histologic Type 4Melanoma 4Hematologic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Adenoma 4Recurrence 3

Interventions

Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Advanced Gastric or Gastroesophageal Junction Adenocarcinoma × Gastrointestinal × Clear all
NCT04435652 2020-06-17

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

Qilu Pharmaceutical Co., Ltd.

Phase 2/3 Unknown
492 enrolled
Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡